跳至主要内容
临床试验/ACTRN12618001482257
ACTRN12618001482257已完成未知

Heme-bound iron (Optifer) in treatment of pregnancy associated iron deficiency anemia

Ahmadi Hospital, Kuwait Oil Company (KOC), Kuwait.0 个研究点目标入组 234 人开始时间: 2018年9月4日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
234

研究概览

简要总结

The hemoglobin and ferritin after Optifer treatment were significantly high compared to the ferrous fumarate treatment. The red blood cells corpuscular volume and red blood cells corpuscular hemoglobin were significantly high after Optifer compared to the ferrous fumarate treatment. The rates of poor compliance and gastrointestinal intolerance were significantly high in the ferrous fumarate treatment compared to Optifer treatment.

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Treatment

入排标准

年龄范围
20 Years 至 40 Years(—)
性别
Female

入选标准

  • Inclusion criteria includes; pregnant women more than or equal 20 years old, 14-26 weeks` gestation, with hemoglobin less than or equal 10 gm/dl (8-10 gm/dl) due to iron deficincy anemia.
  • Iron deficiency anemia diagnosed by the following parameters; hemoglobin concentration (gm/dl), serum ferritin (ug/l), mean corpuscular volume (MCV) and mean corpuscular hemoglobin (MCH).

排除标准

  • Pregnant women with anemia other than iron deficiency anemia and/or received blood transfusion during current pregnancy will excluded from this study.

研究者

发起方
Ahmadi Hospital, Kuwait Oil Company (KOC), Kuwait.

相似试验

Heme-bound iron (Optifer) in treatment of pregnancy... | 临床试验